Pdb44 - The Health Economic Value of Short-Term Cardiovascular Benefits Associated With SGLT-2i From CVD-Real

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.749
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Pdb43 - The Costs and Results of Incretins’and SGLT-2i Diabetes Therapy in Bulgaria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

The Expectation Hypothesis of the Term Structure of Very Short-Term Rates: Statistical Tests and Economic Value☆

Journal of Financial Economics
ManagementFinanceEconomicsStrategyAccountingEconometrics
2008English

Navigating the “MACE” in Cardiovascular Outcomes Trials and Decoding the Relevance of Atherosclerotic CVD Benefits Versus Heart Failure Benefits

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

The Long and the Short of Benzodiazepines and Sleep Medications: Short-Term Benefits, Long-Term Harms?

Neurotherapeutics
NeurologyPharmacology
2020English

Does Gender Influence the Cardiovascular Benefits Observed With Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors? A Meta-Regression Analysis

Cardiology and Therapy
2016English

Short-Term Modelling of the Controlled Cardiovascular System

ESAIM: Proceedings
2002English

Short-Term Cardiovascular Response to Short-Radius Centrifugation With and Without Ergometer Exercise

Frontiers in Physiology
Physiology
2018English

The Long-Term Health Benefits of Receiving Treatment From Qualified Midwives at Birth

Journal of Development Economics
DevelopmentEconomicsEconometrics
2018English

Economic Impact Associated With Pharmaceutical Interventions in Cardiovascular Disease

Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy